Davis Mark Steven 4
4 · MYRIAD GENETICS INC · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Myriad Genetics (MYGN) Director Mark Davis Receives RSU Award
What Happened
Mark Steven Davis, a director of Myriad Genetics, was granted 59,701 restricted stock units (RSUs) on June 4, 2026. The grant is reported at $0.00 per share (no cash paid) — total immediate value shown as $0 — and is recorded on an SEC Form 4 as an award (transaction code A).
Key Details
- Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (next-day filing).
- Award: 59,701 RSUs; reported acquisition price $0.00 (grant); total immediate value $0.
- Shares owned after transaction: not specified in the provided filing.
- Footnote: RSUs granted under the Issuer's 2026 Equity Incentive Plan. Each RSU converts to one share upon vesting. Vesting occurs on the earlier of (a) the first anniversary of the grant or (b) the date of the next annual meeting of stockholders.
Context
RSU grants to directors are a common form of equity compensation and do not involve an out‑of‑pocket purchase. Because these units vest in the future, they do not represent immediately tradable shares unless vested and delivered. This filing reports an award (not a buy or sell) and was filed promptly the day after the grant.
Insider Transaction Report
Form 4
Davis Mark Steven
Director
Transactions
- Award
Common Stock
[F1]2026-06-04+59,701→ 106,665 total
Footnotes (1)
- [F1]Consists of restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan, as amended. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests upon the earlier of (a) the first anniversary of the date of grant or (b) the date of the next annual meeting of stockholders following such grant.
Signature
By: Justin Hunter For: Mark S. Davis|2026-06-05